This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a 3-year RCT. The trial was multi-centred and multi-national. Patients from 32 countries were recruited. The randomisation method used to allocate the patients to the alternative treatment arms was not reported in this paper. A double-blind method for assessment of the outcomes was reported. The design of this trial was described in full elsewhere (Pauwels et al. 2003 ).
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. For patients who dropped out, effectiveness data were linearly extrapolated to the full 3-year study period. The two groups were shown to be comparable in demographic terms, clinical characteristics and drug use at baseline. No adjustment for confounding factors was reported. The main health outcome used in the analysis was asthma symptom-free days (SFDs), which was defined as a 24-hour period with no asthma symptoms. The authors also reported the reduction in hospital stay, emergency room visits and the hazard rate of severe asthma-related events (i.e. events requiring hospitalisation or emergency treatment due to worsening of asthma, or death due to asthma) for patients receiving budesonide, compared with those receiving placebo.
Indirect Costs
Given that the trial population included both children and adults, lost work and school days were accounted for as productivity costs. The cost of a day's absence from work was calculated using the human capital approach, while absences from school were given the same value as absences from work. The costs were discounted at a rate of 3%.
Currency
Eight different local currencies were used in the analysis. These were US dollars ($), Australian dollars (Aus$), Canadian dollars (Can$), Chinese yuan (Y), French francs (Ffr), Spanish pesetas (Pts), Swedish kroner (SEK) and UK pounds sterling ().
Sensitivity analysis
A probabilistic sensitivity analysis may have been performed since 95% confidence intervals were reported for the estimation of incremental cost-effectiveness ratios (ICERs). However, the authors did not report whether any sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section. Estimations of SFDs per country were not reported.
Cost results
The total cost estimates per country were not reported.
Synthesis of costs and benefits
ICERs were estimated as the extra cost incurred per additional SFD obtained with treatment with budesonide when compared with placebo. These ICERs were reported in local currencies. From the perspective of a health care payer, budesonide would be the dominant strategy in Australia (with an incremental cost -Aus$2.2 per additional SFD obtained). In Sweden, Canada, France, Spain, UK, China and the USA, the ICERs ranged from $2.4 to $11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden, while in the countries where an additional cost was required, the ICERs ranged from $0.1 to $9.2 per SFD.
Authors' conclusions
Early intervention with budesonide was shown to significantly improve the number of symptomatic-free days (SFDs) experienced by patients with mild persistent asthma.
CRD COMMENTARY -Selection of comparators
A placebo arm was used as the comparator. This approximated usual asthma therapy, as would be practised in the various participating countries (although no more details of these current practices were provided). You should decide whether this could be a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence was derived from an RCT. This was appropriate for the study question since this type of design is less subject to bias. The methods used to select the patients and to randomly allocate them to the study arms were not reported in this paper. Thus, it was not possible to assess whether the methods used were appropriate. The patient groups were shown to be comparable at analysis in terms of demographic and clinical characteristics, and drug use at baseline. An intention to treat analysis was performed, which is the optimal type of analysis to estimate the true benefit derived from the study intervention. Although not mentioned by the authors, the study sample is likely to have been representative of the study population on account of its relatively large size. The implications of using
